Perspective Therapeutics, Inc. · AMEX:CATX
Perspective Therapeutics — Investor Presentation (March 2025)
51 slides from Perspective Therapeutics's investor presentation, Mar 4, 2025
Slide 1: Corporate Presentation
PERSPECTIVE THERAPEUTICS Corporate Presentation NYSE AMERICAN: CATX
Slide 2: Legal Disclaimers
Legal Disclaimers This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words such as “may,” “will,” “s
Slide 3: Developing the Next Generation of Targeted Therapies
Developing the Next Generation of Targeted Therapies
Slide 4: Broad Proprietary Pipeline
Broad Proprietary Pipeline Three lead programs in clinic with multiple programs in preclinical development Program . (lareet) Target Disease VMT01/02 Melanoma (cir) (MC1R Imaging & Therapy) Neuroendocrine Tumors VMT-a-NET (ssTR2) Other SSTR2 Expressing Tumors PSV359 " " ait PSV40X (Small Molecule) P
Slide 5: Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment
Radiopharmaceutical Therapy Poised to Revolutionize Oncology Treatment Perspective’s pipeline and platform has the potential to significantly expand the breadth of tumors addressed by RPT
Slide 6: The Theranostics Advantage
The Theranostics Advantage Imaging in animal models and human patients facilitates peptide optimization and derisking imaging studies Generate Novel A Development Optimize “ Cee Targeting ws s Gra caimit FIH Imaging Candidate IND Moieties In Vivo Nomination Compound Compound Compound 3-301 3-421 59+
Slide 7: Perspective’s Innovative Platform
Perspective’s Innovative Platform
Slide 8: Perspective’s Radiopharmaceutical Platform Optimized for a Broader Therapeutic Window
Perspective’s Radiopharmaceutical Platform Optimized for a Broader Therapeutic Window
Slide 9: Lead-212: The Optimal Therapeutic Isotope
Lead-212 (2!2Pb): The Optimal Therapeutic Isotope 212Pb provides numerous advantages over beta particle radiotherapies and other alpha emitters Rationale favoring Lead (??2Pb) ae i : Lutetium (?77Lu) Actinium (225Ac) Lead (212Pb) 6 radiation a radiation a radiation a. ' 7 + § Potency Cr) Alpha parti
Slide 10: Proposed Mechanism of Action for 212Pb
Proposed Mechanism of Action for 212Pb
Slide 11: Perspective’s Proprietary Chelator Has Been Optimized for Lead-Based RPTs
Perspective’s Proprietary Chelator Has Been Optimized for Lead-Based RPTs
Slide 12: Platform
Platform Pb-based Theranostics Enable Both Diagnosis and Targeted Treatment of Cancer Identical distribution of 2°2Pb and 2!Pb for imaging and treatment, respectively Imaging Cancer Cell 203Pbh Patient selection Dosimetry: T,,, = 52h V2 i 2°3Pb can be used i Linker to establish *"?Pb pharmacokinetic
Slide 13: Pre-Targeting Platform
Pre-Targeting Platform Potential to Significantly Expand Therapeutic Window by Utilizing Different Kinetics of Proteins and Small Molecules! ‘-) Administer cold modified monoclonal in Pg antibody or targeting protein r 3) Administer radiolabeled ligand Ligand binds only to modified mAb After several
Slide 14: Perspective’s Pre-Targeting Platform
Perspective’s Pre-Targeting Platform
Slide 15: Supply Chain and Manufacturing Infrastructure
Supply Chain and Manufacturing Infrastructure
Slide 16: On-Demand Order Fulfillment at Regional Sites to Deliver Finished Products
On-Demand Order Fulfillment at Regional Sites to Deliver Finished Products
Slide 17: Supply Chain & Manufacturing
Supply Chain & Manufacturing Regional Manufacturing Allows Commercialization of 2!2Pb-labeled Finished Products The “network effect” designed to ensure reliable commercial supply for ready-to-inject therapeutics Sites Today 2027+ 2029 Population Radius “11 hrs Coralville, IA Clinical Supply Somerset
Slide 18: Neuroendocrine Tumors: VMT-α-NET
Neuroendocrine Tumors: VMT-⍺-NET
Slide 19: Clinical Pipeline
Clinical Pipeline Neuroendocrine Tumors: VMT-a-NET Targeting the somatostatin receptor to treat neuroendocrine and other cancers Neuroendocrine cells are specialized cells that secrete hormones and other bioactive substances Disease Most neuroendocrine tumors highly express somatostatin receptor typ
Slide 20: Perspective’s Platform Demonstrates Superior Therapeutic Window: VMT-α-NET
Perspective’s Platform Demonstrates Superior Therapeutic Window: VMT-a-NET In-house discovery capabilities deliver differentiated molecules Key Takeaways vs Generic Compounds Shows Significant Improvement vs Standard of Care in Preclinical Models Preclinical Studies: Decreased Off-Target Toxicity, S
Slide 21: 203Pb SPECT Imaging Reveals Favorable VMT-α-NET Properties
203Pb SPECT Imaging Reveals Favorable VMT-a-NET Properties” Rapid Tumor Targeting High Tumor and Renal Clearance Retention * Tumors visible within 1 hour indicates rapid binding to SSTR2 target High intensity above background Xd ; . implies excellent therapeutic : window — = . bd Unbound drug in bla
Slide 22: Trial Design: [212Pb]VMT-α-NET Phase 1/2a For Neuroendocrine Tumors
Trial Design: [212Pb]VMT-⍺-NET Phase 1/2a For Neuroendocrine Tumors
Slide 23: Anti-Tumor Activity
Anti-Tumor Activity Preliminary response assessment by RECIST v1.1 showed 3 responses in 7 patients from Cohort 2 Percent change in sum of diameters from baseline —@— (°Pb]VMT-o-NET 2.5 mCi (92.5 MBq) —@®— [22Pb]VMT-a-NET 5.0 mCi (185 MBq) 20% 10% 7% 2.6% sD sD sD uPR uPR PR ox | 5.2% | — PD sD sD -
Slide 24: Signal of Sustained Anti-Tumor Activity
Signal of Sustained Anti-Tumor Activity
Slide 25: [212Pb]VMT-α-NET Was Well Tolerated
[212Pb]VMT-α-NET Was Well Tolerated
Slide 26: No Decline in Renal Function Observed
No Decline in Renal Function Observed
Slide 27: Conclusion & Next Steps
Conclusion & Next Steps [?Pb]VMT-a-NET was well tolerated, supporting rationale for potential dose escalation [222Pb] VMT-a-NET was well-tolerated? * No DLTs * No grade 4, grade 5 AEs or SAEs * No decline in renal function * Hematologic AEs were low in number and low grade * No treatment discontinua
Slide 28: Patient with PR after [212Pb]VMT-α-NET
Patient with PR after [212Pb]VMT-α-NET
Slide 29: Melanoma Program: VMT01/02
Melanoma Program: VMT01/02 Using the melanocortin receptor (MC1R) to target melanoma for imaging and therapy
Slide 30: Melanoma Program: VMT01/02
Melanoma Program: VMT01/02 Using the melanocortin receptor (MC1R) to target melanoma for imaging and therapy Treatment may include surgery, radiation, chemotherapy and immunotherapy Disease * Advanced stages of disease occurs throughout the body requiring aggressive systemic treatment Overview * Hig
Slide 31: Combination [212Pb]VMT01 with Immune Checkpoint Inhibitors
Combination [2?2Pb]VMT01 with Immune Checkpoint Inhibitors Lower radiation dose shows superior efficacy in preclinical combination with ICs Monotherapy [212Pb]VMTO1 Combination Therapy [212Pb]VMTO1 + ICIs 600 @ Control (n=8) 0003 @ /Cls (n=7) > © 19 MBq (n=6) = = "g 80018 19 MBq + ICls (n=7) AS © 3.
Slide 32: [212Pb]VMT01 in Combination: Synergistic Responses in Preclinical Studies
[222Pb]VMTO1 in Combination: Synergistic Responses in Preclinical Studies Single dose of VMTO01 in combination significantly arrested melanoma tumor growth and extended survival immunodeficient human melanoma xenograft model — BRAF-positive* Single dose VMTO1 + BRAFi immunocompetent mouse B16:F10 me
Slide 33: [68Ga]VMT02 PET Imaging in Patient with MC1R Positive Metastatic Melanoma
[®Ga]VMTO2 PET Imaging in Patient with MC1R Positive Metastatic Melanoma Diagnostic peptide demonstrates similar uptake to FDG in tumors 18F-FDG (Standard of Care) [®Ga]vMTo02 Patient information * Male, Asian, 33 years old * [§8Ga]VMTO2: 7 mCi injection, 45 min post-injection imaging 33 | ciinical
Slide 34: Trial Design: [212Pb]VMT01 Phase 1/2a For Metastatic Melanoma
Trial Design: [212Pb]VMT01 Phase 1/2a For Metastatic Melanoma
Slide 35: Preliminary Efficacy of [212Pb]VMT01 Observed at Lower Dose
Preliminary Efficacy of [212Pb]VMTO1 Observed at Lower Dose Per preclinical studies, immunostimulatory effect leading to immune-mediated stable disease hypothesized at lower doses @ [22Pb]VMTO1 Cohort 1: 3.0 mCi (111. MBq) il (22Pb]VMTO1 Cohort 2: 5.0 mCi (185 MBq) Follow-up period A First Response
Slide 36: Treatment Emergent Adverse Events
Treatment Emergent Adverse Events (occurring in ≥ 2 patients and/or Grade ≥ 2)
Slide 37: Conclusion & Next Steps
Conclusion & Next Steps Activity seen in 3 mCi dose cohort supports dose reduction and nivolumab combination [??2Pb]VMT01 was safe at doses studied * At3 mCi and 5 mCi activity levels, [212Pb]VMTO1 was safe and no DLTs were observed * Dosimetry demonstrates high kidney estimates limiting monotherapy
Slide 38: Pan-Cancer Target: PSV359
Pan-Cancer Target: PSV359 Preclinical Efficacy and First in Human Images of Novel Peptide Targeting Fibroblast Activation Protein-alpha (FAP-a) CP) PersPective THERAPEUTICS:
Slide 39: Pan-Cancer Program: PSV359
Pan-Cancer Program: PSV359 Novel peptide targeting fibroblast activation protein-alpha (FAP-a) * FAP-a is expressed in the tumor stroma of many epithelial cancers and on the cell surface of other tumor types Disease * FAP Expression on Tumor Stroma: Non-Small Cell Lung Cancer, Pancreatic, Hepatocell
Slide 40: Pan-Cancer Program: PSV359
Pan-Cancer Program: PSV359 Fibroblast activation protein alpha (“FAP”) is a pan-cancer target In some tumor types, FAP In other cancers, FAP is 4% a is expressed on the cancer primarily expressed on cells as well as on stroma tumor stroma cells and not 3 eh > cells on the cancer cells ¢ . oe . - ~~
Slide 41: Novel Compound Development
Novel Compound Deve In-house peptide synthesis and in vivo capability allows rapid iteration and optimization of novel compounds F - . - Phage display scr 5 | Compound 3-30 [ Compound 3-42 | Compoun AVAV AN & BP, BN dgoorrenen S * Phage display followed by affinity maturation * Bioconjugate chemistr
Slide 42: PSV359 is Active Against FAP-α Expression on Tumor and on Stroma
PSV359 is Active Against FAP-α Expression on Tumor and on Stroma
Slide 43: [68Ga]PSV377 PET Imaging in Patient with Metastatic Colorectal Cancer
[®8Ga]PSV377 PET Imaging in Patient with Metastatic Colorectal Cancer Diagnostic FAP-targeted peptide demonstrates excellent uptake in tumors [?8F]FDG MIP (Standard of Care) [°Ga]PSV377' MIP Patient information: * Male, Asian, 34 years old + [8Ga]PSV377: 3.2 mCi injection, 30 min post-injection imag
Slide 44: FIH Imaging of [212Pb]PSV359 in Different Types of Cancers
FIH Imaging of [2°2Pb]PSV359 in Different Types of Cancers Chondroblastic Osteosarcoma [2°2Pb]PSV359 [2°Pb]PSV359 SPECT/CT ‘> , * =% .* é ° 4hr 18 hr 1 hour 4 hour 18 hour Lesion in head of left humerus aa | ; PF) PERSPECTIVE THERAPEUTICS
Slide 45: Conclusion & Next Steps
Conclusion & Next Steps Preclinical data and first-in-human imaging data supportive of FIH therapeutic study in 2025 Strong scientific rationale * FAP-a is a pan-cancer target that is abundantly expressed in certain cancer cells as well as cancer-associated fibroblasts in tumor lesions and involved
Slide 46: General Corporate Information
General Corporate Information
Slide 47: Deeply Experienced Management Team in Radiopharmaceuticals and Oncology Drug Development
Deeply Experienced Management Team in Radiopharmaceuticals and Oncology Drug Development 20+ years of expertise in biot jology companies; public and private companies; ‘oncology and nuclear pharmacy Thijs Spoor Chief Executive Officer - cotynia Srsissio TEES Veriting 20+ years of experience in life
Slide 48: Strong Intellectual Property Portfolio
Strong Intellectual Property Portfolio Perspective-owned/Exclusively-licensed IP 7 Issued Patents (Expiry in 2037 and 2040, with potential PTE) Composition of matter for melanoma targeted radiopharmaceutical compounds; methods of combination therapies; methods of creating radiopharmaceutical compoun
Slide 49: Strong Financial Position
Strong Financial Position Funding into late 20267 Preliminary cash, cash equivalents and short-term investments as of December 31, 2024 $227 million Based on our current plans, which include advancing current clinical programs based on readout, progressing multiple pre-IND assets towards clinical tr
Slide 50: Slide 50
Slide 51: Abbreviations
Abbreviations AE: adverse event APC: antigen-presenting cell ASCO-GI: ASCO Gastrointestinal Cancers Symposium DAMPs: damage-associated molecular patterns DLT: dose limiting toxicities DOR: duration of response dsDNA: double-stranded DNA EANM: European Association of Nuclear Me: eGFR: estimated glome
Perspective Therapeutics — Investor Presentation (March 2025) on 6ix